Lyra Therapeutics, Inc.LYRA
| Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
---|
Cash and cash equivalents | 75 | 46 | 33 |
---|
Short-term investments | - | - | 65 |
---|
Prepaid expenses and other current assets | 1 | 2 | 3 |
---|
Total current assets | 76 | 48 | 101 |
---|
Property and equipment, net | 2 | 5 | 2 |
---|
Operating lease right-of-use assets | 2 | 1 | 2 |
---|
Restricted cash | 0 | 0 | 1 |
---|
Other assets | 0 | 1 | 3 |
---|
Total assets | 81 | 55 | 110 |
---|
Accounts payable | 1 | 3 | 3 |
---|
Accrued expenses and other current liabilities | 3 | 4 | 9 |
---|
Operating lease liabilities | 1 | 1 | 2 |
---|
Deferred revenue | - | 10 | 1 |
---|
Total current liabilities | 5 | 18 | 14 |
---|
Operating Lease, Liability, Noncurrent | 1 | 0 | 1 |
---|
Deferred Revenue, Noncurrent | - | 2 | 14 |
---|
Total liabilities | 6 | 21 | 29 |
---|
Common Stock, Value, Issued | 0 | 0 | 0 |
---|
Additional paid-in capital | 224 | 228 | 329 |
---|
Accumulated other comprehensive income, net of tax | - | - | 0 |
---|
Accumulated deficit | -150 | -193 | -249 |
---|
Total stockholders’ equity | 74 | 34 | 81 |
---|
Total liabilities and stock and stockholders’ equity | 81 | 55 | 110 |
---|